ABT vs ALKS · P/E 25, rev $44.33B vs P/E 14, rev $1.56B
Abbott Laboratories (ABT) versus Alkermes Plc (ALKS) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
Not investment advice. Open the ABT and ALKS stock pages for the full models.
Not investment advice.